title: Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
abstract: AIDSVAX (VaxGen, Inc., South San Francisco, CA), a possible vaccine to protect against human immunodeficiency virus type 1 (HIV-1) infection, is being tested for efficacy in phase 3 studies. It has been tested for potential efficacy in chimpanzees, and tested for safety and immunogenicity in human clinical studies. Four candidate vaccines, each with a different envelope protein antigen or combination of antigens, have been produced in alum formulations. In both design and clinical testing, AIDSVAX has an excellent safety profile. Because these highly purified proteins were prepared using recombinant DNA technology, there is no possibility of these vaccines causing HIV infection. Having been administered to over 1200 people, the only side effects attributable to AIDSVAX have been local pain and inflammation at the injection site. After immunization, essentially all recipients developed a robust antibody response, including binding and neutralizing antibodies. The neutralizing antibodies peaked after a 12-month boost. Excellent memory is induced. Two phase 3 trials of two bivalent formulations will evaluate their efficacy. One trial will use a bivalent subtype B formulation. This trial in North America will involve 5000 men who have sex with men and heterosexual women at high risk. The other study will use a bivalent subtype B/subtype E formulation. This trial in Thailand and will involve 2500 intravenous drug users. Both studies will be randomized, double-blinded and placebo controlled. The volunteers will be followed for 3 years. The end points of the studies are infection, as defined by seroconversion to standard diagnostic tests, and viral load, as defined by commercial polymerase chain reaction (PCR) tests.
authors.affiliation: VaxGen, Inc., South San Francisco, California 94080, USA.
authors.forename: D P
authors.initials: DP
authors.lastname: Francis
authors.forename: T
authors.initials: T
authors.lastname: Gregory
authors.forename: M J
authors.initials: MJ
authors.lastname: McElrath
authors.forename: R B
authors.initials: RB
authors.lastname: Belshe
authors.forename: G J
authors.initials: GJ
authors.lastname: Gorse
authors.forename: S
authors.initials: S
authors.lastname: Migasena
authors.forename: D
authors.initials: D
authors.lastname: Kitayaporn
authors.forename: P
authors.initials: P
authors.lastname: Pitisuttitham
authors.forename: T
authors.initials: T
authors.lastname: Matthews
authors.forename: D H
authors.initials: DH
authors.lastname: Schwartz
authors.forename: P W
authors.initials: PW
authors.lastname: Berman
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000328:Adult; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D015483:HIV Antibodies / Q000096:biosynthesis; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D008297:Male
chemical_list: D016915:AIDS Vaccines; C112734:AIDSVAX; D015483:HIV Antibodies